The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Head and Neck Cancer
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
Endoscopic Approaches Feasible in Surgery for Sinonasal Cancer
Overall, 87.4 percent of 239 patients achieved negative margins with endoscopic resection.
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups.
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
How to Help Patients With Cancer Find Trustworthy Information Online
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.
Gender Bias in Oncology: Q&A With Dr Narjust Duma
Women are less likely to be introduced by their professional title and most likely to be introduced by first name.
Pembrolizumab Prolongs Survival in Advanced Head, Neck Cancer
Authors recommend pembrolizumab, with or without chemotherapy, as first-line treatment.
Delaying Treatment Worsens Head, Neck Cancer Outcomes
Findings show that survival declines, recurrence increases with delays of more than 60 days.
Next post in Head and Neck Cancer
